— If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel delivery systems building on Company’s dedication to meeting clinicians’ evolving needs — DUBLIN, Sept. 28, 2022 /PRNewswire/ — Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced the submission of a […]
Other News
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 11th, 2022 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the fifth […]
HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)
Patented Technology Allows HeartBeam AIMIGo™ Credit Card-sized Device to Enable a 12-lead ECG Anytime, Anywhere SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent that enables generation of a […]
REVA MEDICAL ANNOUNCES INITIATION OF ENROLLMENT IN THE MOTIV IDE CLINCIAL TRIAL
SAN DIEGO, Sept. 27, 2022 /PRNewswire/ — REVA Medical, LLC, a leader in bioresorbable polymer technologies for vascular applications, today announced that enrollment in the MOTIV pivotal trial has been initiated at clinical centers in both the U.S. and Europe. The study will evaluate the use of the MOTIV® Sirolimus-Eluting Bioresorbable Vascular Scaffold for […]
Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial
REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the activation of three additional sites […]
Teleflex launches new Arrow® Pressure Injectable Midline Catheter Portfolio
Midline options designed to fit the needs of clinicians and patients WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) releases their new Arrow® Pressure Injectable Midline portfolio in the US and Canada, designed to help alleviate line identification confusion. Clinicians can choose between the Arrowg+ard Blue Advance® Midline […]
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey
CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site PRINCETON, N.J., Sept. 27, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that it has received ISO 13485 […]
B. Braun Acquires Clik-FIX® Catheter Securement Devices from Starboard Medical
Acquisition Creates Industry-Leading Portfolio of Catheter Securement Solutions BETHLEHEM, Pa., Sept. 27, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today it has acquired the innovative Clik-FIX catheter securement device portfolio from Starboard Medical, Inc. B. Braun’s acquisition builds on the company’s […]
Catheter Precision Names Fatih Ayoglu as Business Development Manager—EMEA
MT. OLIVE, N.J. & CARLSBAD, Calif.–(BUSINESS WIRE)–Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces the appointment of Fatih Ayoglu to the newly created position of Business Development Manager—EMEA. Mr. Ayoglu will oversee clinical and sales development of Catheter Precision products in Europe, the Middle […]
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock […]



